2,706 Shares in Cencora, Inc. $COR Purchased by Inceptionr LLC

Inceptionr LLC acquired a new position in Cencora, Inc. (NYSE:COR) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,706 shares of the company’s stock, valued at approximately $850,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Assetmark Inc. raised its stake in shares of Cencora by 57.0% during the 4th quarter. Assetmark Inc. now owns 67,281 shares of the company’s stock worth $22,724,000 after purchasing an additional 24,431 shares during the period. ExodusPoint Capital Management LP purchased a new stake in Cencora during the fourth quarter worth about $16,487,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Cencora by 162.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 289,370 shares of the company’s stock worth $97,735,000 after buying an additional 179,086 shares during the last quarter. Impact Partnership Wealth LLC bought a new stake in Cencora in the first quarter worth about $1,170,000. Finally, SEB Asset Management AB bought a new stake in Cencora in the first quarter worth about $134,139,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, Director Lauren M. Tyler purchased 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.38% of the stock is owned by insiders.

Cencora Price Performance

COR opened at $309.67 on Friday. The firm has a 50-day moving average price of $284.52 and a 200-day moving average price of $316.47. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a market capitalization of $60.25 billion, a price-to-earnings ratio of 23.75, a PEG ratio of 1.69 and a beta of 0.58.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the company posted $4.42 earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its Board of Directors has approved a stock repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on COR. Wells Fargo & Company dropped their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Barclays lowered their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Citigroup dropped their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. William Blair initiated coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Finally, Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.